Radioimmunotherapy: designer molecules to potentiate effective therapy.
The evolution of monoclonal antibody forms for radioimmunotherapy and other antibody-based applications has been driven by a series of problems that each new form has introduced. Ehrlich was the first to present the concept that antibodies could be exploited in such a manner. Four decades were required before technological advances allowed the exploration of the potential of antibodies for radioimaging and radioimmunotherapeutic applications. Advances in DNA technology have led to the ability to tailor and manipulate the immunoglobulin molecule for specific functions and in vivo properties. This article discusses the use of monoclonal antibodies for radiotherapy with an emphasis on the problems that have been encountered and the subsequent solutions.
Milenic
D E
DE
Laboratory of Tumor Immunology and Biology, Bethesda, MD 20892, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D010455:Peptides / Q000627:therapeutic use; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D010455:Peptides